Use of platelet-rich fibrin in regenerative dentistry: a systematic review.
OBJECTIVES: Research across many fields of medicine now points towards the clinical advantages of combining regenerative procedures with platelet-rich fibrin (PRF). This systematic review aimed to gather the extensive number of articles published to date on PRF in the dental field to better understand the clinical procedures where PRF may be utilized to enhance tissue/bone formation.
Engineered liver tissue expands after transplant
Many diseases, including cirrhosis and hepatitis, can lead to liver failure. More than 17,000 Americans suffering from these diseases are now waiting for liver transplants, but significantly fewer livers are available.
Which research results in mice will help humans with MS? Now there’s a way to tell
People with multiple sclerosis (MS) know all too well the frustration of hearing that success in treating the disease in mice had little or no effect in humans.
Concise Reviews: Kidney Generation with Human Pluripotent Stem Cells
Chronic kidney disease (CKD) is a world-wide healthcare problem, resulting in increased cardiovascular mortality and often leading to end-stage kidney disease (ESKD) where patients require kidney replacement therapies such as hemodialysis or kidney transplantation
Amniotic fluid stem cells ameliorate bladder dysfunction induced by chronic bladder ischemia in rat
This study investigated the protective effect of human amniotic fluid-derived stem cells (hAFSCs) against bladder overactivity in rat model of atherosclerosis-induced chronic bladder ischemia.
A phase 1 trial of 90Y-Zevalin radioimmunotherapy with autologous stem cell transplant for multiple myeloma
This phase 1 study (clinical trial NCT00477815) was conducted to determine the maximum tolerated dose (MTD) of yttrium-90 ibritumomab tiuxetan (90Y-Zevalin) with high dose melphalan (HDM) therapy in multiple myeloma (MM) patients undergoing autologous stem cell transplantation (ASCT).
In vitro and in vivo imaging and tracking of intestinal organoids from human-induced pluripotent stem cells
Human intestinal organoids (hIOs) derived from human pluripotent stem cells (hPSCs) have immense potential as a source of intestines.
Global CAR T Cell Therapy Market to Reach US$ 8.5 Billion by 2028
The Global Car T Cell Therapy Market is expected to be valued at US$ 8.5 Billion by 2028, as analyzed by Coherent Market Insights. Increasing demand for genetically engineered treatment approach for high success rate in cancer treatment along with growing cancer incidence rate are key factors driving demand for CAR T cell therapy products worldwide.
Engineered T cells for all
Gene-engineered autologous T cells with chimeric antigen receptors (CARs) against CD19 (CART19 cells) have been effective against patients with CD19+ B cell malignancies.
UCLA Launches First-of-Its-Kind Stem Cell Trial to Combat Cancer
Scientists at UCLA have launched the first genetically engineered blood stem cell clinical trial to fight cancer thanks to $20 million in voter-approved funds earmarked for stem cell research, university officials announced Monday.
